Epidemiological analysis of second primary malignant neoplasms in cancer survivors aged 85 years and older: a SEER data analysis (1975-2016).
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
08 07 2022
08 07 2022
Historique:
received:
09
12
2021
accepted:
28
06
2022
entrez:
8
7
2022
pubmed:
9
7
2022
medline:
14
7
2022
Statut:
epublish
Résumé
Cancer burden in patients aged 85 years and older has rapidly increased accompanying the decrease in mortality, which is raising the concern of developing second primary malignant neoplasms (SPM). This study aimed to investigate the epidemiology of the SPM in this population in the US by using the surveillance, epidemiology, and end results database (1975-2016). The cumulative incidence of developing a SPM was calculated by the Fine and Gray model. Standardized incidence ratios (SIR) were calculated via Poisson regression. The relative post-SPM survival rate was calculated by the Kaplan-Meier method. Male patients with skin melanoma, kidney and renal pelvis and urinary bladder cancers had high cumulative incidences (15.32%, 13.55%, and 12.26%, respectively) and increased SIRs (1.47, 1.44, and 1.16, respectively) for developing SPMs. Female patients with skin melanoma and urinary bladder cancers had high cumulative incidences (10.18% and 7.87%, respectively) and increased SIRs (1.34 and 1.18, respectively). In general, the incidence of SPM cases increased over time. The median latency ranged from 17 to 37 months. A less than 50% of patients had 1-year post-SPM survival. In conclusion, some of these patients had an increased risk of the SPM, with poor survival.
Identifiants
pubmed: 35803964
doi: 10.1038/s41598-022-15746-x
pii: 10.1038/s41598-022-15746-x
pmc: PMC9270446
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
11688Informations de copyright
© 2022. The Author(s).
Références
Cancer. 2014 May 1;120(9):1290-314
pubmed: 24343171
Sci Rep. 2021 Oct 5;11(1):19748
pubmed: 34611235
Am J Epidemiol. 2021 May 4;190(5):836-842
pubmed: 33089310
JAMA Oncol. 2017 Nov 01;3(11):1554-1557
pubmed: 28426850
Int J Clin Oncol. 2019 Aug;24(8):934-940
pubmed: 30888527
Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1029-36
pubmed: 27371756
ESMO Open. 2017 May 2;2(2):e000172
pubmed: 28761745
J Registry Manag. 2017 Winter;44(4):130-135
pubmed: 30133428
Br J Cancer. 2012 Mar 27;106(7):1353-60
pubmed: 22353805
Am J Med Sci. 2014 Jul;348(1):65-70
pubmed: 24805784
Int J Cancer. 2019 Jul 1;145(1):143-153
pubmed: 30613963
CA Cancer J Clin. 2019 Nov;69(6):452-467
pubmed: 31390062
Cureus. 2018 Mar 28;10(3):e2384
pubmed: 29850379
Gastric Cancer. 2016 Apr;19(2):490-497
pubmed: 25772342
Ann Transl Med. 2020 May;8(10):638
pubmed: 32566575